Clinical trials: CEACAM5
Metastatic Colorectal Cancer
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288).
- Trial name
- NCT01273402
- Testing
- TF2/IMP288
- Where
- United States
- Sponsor
- Gilead Sciences
Solid Tumors
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical study of single-agent RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA) positive solid…
- Trial name
- NCT02324257
- Testing
- RO6958688, Obinutuzumab, Tocilizumab
- Where
- 21 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor Cancer
Phase II Study of LM-24C5
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
- Trial name
- NCT07387081
- Testing
- LM-24C5
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- LaNova Medicines Limited
the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients
The Relationship Between the Tumor Markers and Interstitial Lung Disease
The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.
- Trial name
- NCT04597814
- Testing
- No Intervention
- Where
- China
- Volunteers
- 13 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Colorectal Cancer
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with…
- Trial name
- NCT03866239
- Testing
- Obinutuzumab, Atezolizumab, Cibisatamab
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy…
- Trial name
- NCT00004085
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology